Hey there, time traveller!
This article was published 14/3/2013 (1405 days ago), so information in it may no longer be current.
A look at the diabetes drugs under investigation by the U.S. Food and Drug Administration over possible risks of pancreas inflammation and cellular changes in the pancreas that occur before cancer.
DRUG CLASS: GLP-1 mimickers, taken by nearly 1 million Americans.
HOW THEY WORK: Injections needed anywhere from twice a day to once a week, they make the body produce more insulin to lower blood sugar.
MAKER: Bristol-Myers Squibb Co.
CHEMICAL/BRAND NAMES: exenatide/Byetta and Bydureon
MAKER: Novo Nordisk A/S:
CHEMICAL/BRAND NAMES: liraglutide/Victoza
DRUG CLASS: DPP-4 inhibitors, taken by about 1.6 million Americans.
HOW THEY WORK: Pills taken once or twice a day, they stimulate insulin production and limit release of a hormone that raises blood sugar levels.
MAKER: Merck & Co.
CHEMICAL/BRAND NAMES: sitagliptin/Januvia, Janumet, Janumet XR, Juvisync
MAKER: Bristol-Myers Squibb Co. & AstraZeneca PLC
CHEMICAL/BRAND NAMES: saxagliptin/Onglyza and Kombiglyze
MAKER: Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc.
CHEMICAL/BRAND NAMES: linagliptin/Jentadueto and Tradjenta
MAKER: Takeda Pharmaceuticals Co. Ltd.
CHEMICAL/BRAND NAMES: alogliptin/Nesina, Kazano and Oseni
Source: Company websites, health data firm Kantar Health.